Connect with Us
602 Park Point Drive, Suite 225, Golden, CO 80401 – +1 303.495.2073
© 2024 Medical Affairs Professional Society (MAPS). All Rights Reserved Worldwide.
MAPS members represent the full range of Medical Affairs professionals, from those leading or working in large organizations, to those tasked with starting a Medical Affairs function at startup or emerging organizations. Here, MAPS speaks with Lobna Salem, Regional Chief Medical officer Developed Markets& Japan Australia and New Zealand at Viatris, about the process of building Medical Affairs from scratch.
Pharmaceutical companies continue to evolve the way they operate, both internally and within the external environment. A variety of factors drive this evolution including societal expectations, continued changes in healthcare systems across geographies, advances in digital technology and its application (as highlighted during COVID 19), and complex legal, regulatory, compliance, and privacy obligations. As a result of these factors, the Medical Affairs (MA) function will become increasingly critical due to its unique positioning, as follows:
This paper explores the MA-based medical insights function and insights-related activities from an MA operational perspective, and identifies basic operational elements required to establish medical insights as a core strategic MA function.
Medical Affairs is a function within the biopharmaceutical, consumer healthcare, and MedTech industries that sits alongside other functions including Research & Development (R&D) and Commercial as one of the strategic pillars of the industry. R&D develops new drugs, devices and diagnostics; Commercial markets and sells these products; and Medical Affairs generates and communicates data that help healthcare professionals (HCPs), payors, policy makers and others make informed decisions that ensure the best use of treatments to benefit patients. In this way, Medical Affairs plays a vital role in providing scientific evidence and understanding to appropriately change clinical practice.
Just as there are many roles within R&D and Commercial, individuals working within Medical Affairs are responsible for many activities, especially including the following:
At the MAPS 2022 Global Annual Meeting, MAPS sits down to chat with José Borbolla, Global Executive Medical Director at Esai, and Augusto Grinspan, VP Medical Affairs and Head LATAM with Merck KGaA about developments in the practice and direction of Medical Affairs in Latin America. Augusto and José are also co-chairs of the MAPS Latin America Chapter.
This webinar will analyze the current state of Medical Affairs in Japan, highlight progress made and provide suggestions on what we can do together to make Medical Affairs in Japan even more effective.
This webinar will be covering:
1.   MA in Japan today: progress and highlights
a.   Leadership requirements in Japan to bring MA to the next level
b.   MA has become more strategic across all companies
c.    What are the competencies required to succeed?
2.   Looking into the future of MA in Japan
a.   How to engage more with Patients/Patient Advocacy groups
b.   How to bring more value to customers, scientific leaders and health systems
c.    How to better engage academia and health authority group through scientific exchange
3.   Opportunities for improving effectiveness
a.   Differentiation of MSL and Medical Rep roles- how are companies differentiating despite the regulations?
As Medical Affairs professionals, it's easy to focus on the tasks that are right in front of us everyday. In this interview with Monica de Abadal, SVP and Head of Medical Affairs, North America we sat down at the MAPS 2022 Global Annual Meeting to take a step back. Here is how Medical Affairs benefits patients and society. Watch the full interview here.
This podcast, recorded at the MAPS 2022 Global Annual Meeting, addresses the unique position of Medical Affairs in the rare disease space & how our work in this area is essential for patient benefit.
Medical Affairs describes itself as a third strategic pillar in the biopharmaceutical and MedTech industries alongside R&D and Commercial. But is this truly the case or is Medical Affairs' strategic role still aspirational? And if it is in some ways aspirational, what does Medical Affairs need to do in order to truly achieve its position alongside R&D and Commercial? Here, three Medical Affairs leaders discuss these questions and offer their perspective for the future of the function.
Insights management is widely acknowledged across the pharmaceutical industry as being pivotal for informing and influencing strategy. Despite this, companies approach insights gathering in a fragmented and inefficient manner, with a lack of consistent frameworks. The risk is a loss of strategic advantage due to information being synthesized too slowly, and decisions being made on old or incomplete data.
Should teams be focussing on people, processes or technology when considering how to improve their insights gathering? The key to developing a robust insights gathering approach is striking the right balance between all three. Join this webinar to understand key steps that all Medical Affairs teams can take now to move towards a more holistic approach to insights gathering activities, allowing them to make better, faster decisions.
This webinar will address:
One of the pandemic’s silver linings may well be gains in participation levels and the volume and quality of insights generated by eliminating the constraints of face-to-face interaction.
602 Park Point Drive, Suite 225, Golden, CO 80401 – +1 303.495.2073
© 2024 Medical Affairs Professional Society (MAPS). All Rights Reserved Worldwide.